Research & Reviews: Journal of Medical and Health Sciences

e-ISSN:2319-9865
p-ISSN:2322-0104

A Short Note on Disseminated Intravascular Coagulation

Sindhu P*

Department of Pharmacy, Vaageswari Institute of Pharmaceutical Sciences, Thimapur, Karimnagar, Telangana, India

Review Article

Received: 24/09/2016
Revised: 27/09/2016
Accepted: 30/09/2016

***For Correspondence**

Sindhu P, Vaageswari institute of pharmaceutical sciences, Thimapur, karimnagar, Telgana, India.

Keywords: Appalling Immunological Reactions, Hepatic Disease, Serum Fibrinogen, Thrombosis

E-mail: sindhureddy.pingili@gmail.com

ABSTRACT

Disseminated intravascular coagulation is a recurrent complexity in sepsis that is mainly associated with adverse outcomes and increased mortality in patients. Besides to the uncurbed generation of thrombi all through the vasculature in patients. DIC often devour large quantities of clotting factors abandon the patient credulous to haemorrhaging. Because of these difficulties, patients even receive anticoagulants mainly to treat unimpeded clotting, often with mixed results. Systemic inflammation mainly has the capability to trigger and intensify coagulation and likewise potential therapies usually for the treatment of sepsis- analogous DIC need to place the interaction linking inflammation and coagulation. Current studies have proposed that platelets and neutrophil extracellular traps are the cue mediators of infection induced coagulation. It may cause mortality in children.

DISSEMINATED INTRAVASCULAR COAGULATION

Disseminated intravascular coagulation (DIC), also called as disseminated intravascular coagulopathy is a process caused by pathological conditions mainly characterized by the extensive activation of the clotting stream that mainly results in blood clots formation in small blood vessels all through the body [1-15].

Signs and manifestations of DIC:

- Formation of blood clots,
- Reduced blood pressure,
- Destruction of organs,
  Eg: Pancreatitis
- Obstetric affliction,
  Eg: Embolism of amniotic fluid, Placental abruption,
- Abnormalities in vascular functions,
- Dreadful hepatic failure,
- Appalling immunological reactions,
- Internal bleeding such as blood in stool or urine as well as haemorrhage,
- Contuse and small red dots formation on skin,
- Bleeding at wound sites, surgical sites, catheter sites or intravenous needle,
- Bleeding from mucosal sites- such as gums, mouth, nose,
- Formation of clots in the heart may cause acute myocardial infarction [16-36].

Inducement of DIC

When a person is injured, blood proteins form blood clots which travel to the site of injury to stop the bleeding. If a person has DIC, these proteins begin to abnormally active all through the body. It may be mainly because of infection, inflammation, or cancer [37-45].

Formation of small blood clots in blood vessels. These clots may block the vessels and carve supply of blood to organs mainly brain, liver, or kidneys.

Famine of blood flow can cause organ damage and it mainly ceases working.

e-ISSN:2319-9865
p-ISSN:2322-0104

Prospects for DIC

- Reactions caused due to blood transfusion,
- Cancer, particularly with some palpable types of leukemia,
- Pancreas inflammation,
- Blood infection, particularly by fungus or bacteria,
- Complications during pregnancy,
- Hepatic disease,
- People who undergone surgery,
- Anesthesia either local or general,
- Persons with serious tissue damage mainly injury of head, trauma and burns [46-61].

Diagnosis of DIC

- Total blood cell count with examining the blood smear,
- Degradation product of fibrin,
- Time for partial thromboplastin,
- Time for prothrombin,
- Serum fibrinogen,
- Total blood cell count from the collected sample,
- Test for D-dimer [32-73].

TREATMENT

Underlying condition should be detected for the treatment of DIC. In Cases of significant bleeding fresh frozen plasma or transfusions of platelets can be considered, or those with a proper planned procedure for invasion. Quarry goal of parallel transfusion mainly rely on clinical situation. In those cryoprecipitate should be considered with a low level fibrinogen [74-79].

Because of trhe risk of bleeding thrombosis treatment with anti-coagulants like heparin is rarely used.

In people with severe sepsis and DIC, Human activated recombinant Protein C was previously advised but α-Drotrecogain has been shown to give zero benefit so it was introverted from the market in the year 2011.

“Last resort” was proposed as Recombinant factor VII mainly in people with serious hemorrhage because of obstetric or other reasons [80-87].

PROJECTION

It varies depending on the underlying disorder and the magnitude of intravascular thrombosis. The projection for those with DIC, despite of any cause [88-91].

CONCLUSION

Most common feature in all types of DIC is wild spread and dogged activation. DIC may be categorized as it can cause organ failure, bleeding, massive bleeding and other types. Signs and manifestations of DIC mainly leads to an increased possibility of mortality and morbidity. Pathogenesis of DIC has evolved in superior strategies for management of clinical conditions, including direct diagnostic basis and probable beneficial reinforce treatment options [92-102].

REFERENCES

1. Taylor FB, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-1330.
2. Wada H. Disseminated intravascular coagulation. Clin Chim Acta 2004;344:13-21.
3. Levi M, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009;145:24-33.
4. Wada H, et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010;125:6-11.
5. Di Nisio M, et al. Diagnosis and treatment of disseminated intravascular coagulation; guidelines of the Italian society for haemostasis and thrombosis (SISET). Thromb Res 2012;129:e177-e184.
6. Wada H, et al. The scientific standardization committee on DIC of the international society on thrombosis haemostasis; guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013;11:761-767.

7. Wada H, et al. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. Expert Rev Hematol 2012;5:643-652.
8. Wada H, et al. Plasma level of IL-1β in disseminated intravascular coagulation. Thromb Haemost 1991;65:364-368.
9. Wada H, et al. Plasma level of tumor necrosis factor in disseminated intravascular coagulation. Am J Hematol 1991;37:147-151.
10. Brinkmann V, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-1535.
11. Fuchs TA, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010;107:15880-15885.
12. Massberg S, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010;16:887-896.
13. Hatada T, et al. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005;94:975-979.
14. Wada H, et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost 1995;74:848-852.
15. Wada H, et al. Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol 1993;43:190-194.
16. Kawasugi K, et al. Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. Thromb Res 2011;128:186-190.
17. Kobayashi N, et al. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the research committee on DIC in Japan. Bibl Haemotol 1983;49:265-275.
18. Gando S, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients; comparing current criteria. Crit Care Med 2006;34:625-631.
19. Gando S, et al. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thromb Hemost 2005;11:71-76.
20. Takemitsu T, et al. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost 2011;105:40-44.
21. Bick R. Disseminated intravascular coagulation;objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Semin Thromb Hemost 1996;22:69-88.
22. Levi M and Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-592.
23. Redl H, et al. Thrombomodulin release in baboon sepsis;its dependence on the dose of Escherichia coli and the presence of tumor necrosis factor. J Infect Dis. 1995;171:1522-1527.
24. Boehme MW, et al. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils;in vivo and in vitro studies. Immunology. 1996;87:134-1340.
25. Lin SM, et al. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Crit Care Med. 2008;36:683-689.
26. Abeyama K, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005;115:1267-1274.
27. Saito H, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation;results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31-41.
28. Levi M. The coagulant response in sepsis. Clin Chest Med. 2008;29:627-642.
29. Sawdey M, et al. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem. 1989;264:10396-10401.
30. Madoiwa S, et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol. 2006;84:398-405.
31. Koyama K, et al. Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis;a prospective observational study. Crit Care. 2014;18:R13.
32. Sawamura A, et al. Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. Thromb Res. 2009;124:608-613.

e-ISSN:2319-9865
p-ISSN:2322-0104

33. Palmer L and Martin L. Traumatic coagulopathy-part 1; pathophysiology and diagnosis. J Vet Emerg Crit Care. 2014;24:63-74.
34. Matthay MA. Severe sepsis-a new treatment with both anticoagulant and anti-inflammatory properties. N Engl J Med. 2001;344:759-762.
35. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989;320:365-376.
36. Dokai M, et al. Local regulation of neutrophil elastase activity by endogenous alpha1-antitrypsin in lipopolysaccharide-primed hematological cells. Thromb Res. 2011;128:283-292.
37. Moir E, et al. Polymorphonuclear leucocytes have two opposing roles in fibrinolysis. Thromb Haemost. 2002;87:1006-1010.
38. Wu K, et al. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase;the evaluation of its physiologic relevance in fibrinolysis. Blood. 1995;86:1056-1061.
39. Bach-Gansmo ET, et al. Impaired clot lysis in the presence of human neutrophil elastase. Thromb Res. 1995;80:153-159.
40. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589-600.
41. Ono T, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation; its correlation with development of renal failure. Blood. 2006;107:528-534.
42. Xu J, et al. Extracellular histones are major mediators of death in sepsis. Nat Med. 2009;15:1318-1321.
43. Papayannopoulos V, et al. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol. 2010;191:677-691.
44. Ma R, et al. Extracellular DNA traps released by acute promyelocytic leukemia cells through autophagy. Cell Death Dis. 2016;7:e2283.
45. Joshi N, et al. Coagulation-driven platelet activation reduces cholestatic liver injury and fibrosis in mice. J Thromb Haemost. 2015;13:57-71.
46. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101:3765-377.
47. Kohno I, et al. A monoclonal antibody specific to the granulocyte-derived elastase-fragment D species of human fibrinogen and fibrin; its application to the measurement of granulocyte-derived elastase digests in plasma. Blood. 2000;95:1721-1728.
48. Angstwurm MW, et al. New disseminated intravascular coagulation score; A useful tool to predict mortality in comparison with Acute Physiology and Chronic Health Evaluation II and Logistic Organ Dysfunction scores. Crit Care Med. 2006;34:314-320.
49. Shao Q, et al. Chronic disseminated intravascular coagulation induced by left atrial thrombus in a patient with giant "normal" heart: A case report. Medicine (Baltimore). 2016;95:e5501.
50. Levi M and Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10:222.
51. Levi M. Diagnosis and treatment of disseminated intravascular coagulation. Int J Lab Hematol. 2014;36:228-236.
52. Levi M and Van Der Poll T. Thrombomodulin in sepsis. Minerva Anestesiol. 2013;79:294-298.
53. Izgaryshev AV, et al. Hydrolysis of the red blood cells of pig and cattle to ensure optimum conditions for the manufacturing of iron-containing products having maximum heme iron. Biol Med (Aligarh). 2016;8:330.
54. van Tol RR, et al. Inclusion of C-reactive protein and white blood cell count in diagnostic workup of patients with clinically suspected appendicitis stratifies for imaging. J Med Diagn Meth. 2016;5:212.
55. Das M, et al. Computational analysis of ultra-structural images of red blood cells. Oncol Trans Res. 2015;1:104.
56. Yunfu Lv, et al. Analysis of peripheral blood cells due to adults posthepatitic cirrhotic portal hypertension and their postoperative prognosis. J Hypertens (Los Angel). 2015;4:210.
57. Helfritz FA, et al. Perioperative white blood cell count as a marker for patient and graft survival after orthotopic liver transplantation. J Hepatol Gastroint Dis. 2015;1:106.
58. Naba T, et al. Hemolytic anemia with fragmented red blood cells following vascular access grafting for hemodialysis in a patient with chronic kidney disease. J Blood Disord Transfus. 2014;5:201.
59. Cohn S and Keric N. Impact of the age of transfused red blood cells in the trauma population. J Blood Lymph. 2014;4:118.
60. Sadaka F. Red blood cell transfusion in sepsis; A review. J Blood Disord Transfus. 2012;S4:001.

61. Cerdas-Quesada C. Bacterial sepsis secondary to red blood cells transfusion despite routine platelet culture screening; A case report. J Blood Disord Transfus. 2012;3:130.
62. Zaets SB. Do we have enough direct evidence to postulate that abnormally shaped red blood cells impair microvascular blood flow in critical conditions? Anatom Physiol. 2013;3:e112.
63. Kadam S, et al. A canonical transforming growth factor beta-dependent signaling pathway is present in peripheral blood cells of cancer patients with skeletal metastasis. J Mol Biomark Diagn. 2013;4:153.
64. Meng T and Dai M. Plasmapheresis treatment for a pregnant woman with extremely severe hyperlipidemic pancreatitis; A case report. J Clin Case Rep. 2016;6:827.
65. Han Z, et al. Vitamin D deficiency in patients with pancreatitis; Is vitamin D replacement required? Pancreat Disord Ther. 2016;6:172.
66. Babi MA, et al. A first clinical case report of west-nile viral meningoencephalitis complicated with acute pancreatitis in North America. J Meningitis. 2016;1:104.
67. Maraví-Poma E and Zubia-Olaskoaga F. Current status in the management of acute pancreatitis. Emergency Med. 2015;6:297.
68. Hou YC, et al. Therapeutic efficacy of spleen-derived mesenchymal stem cells in mice with acute pancreatitis. J Stem Cell Res Ther. 2015;5:318.
69. Madej K, et al. Nocardiosis in a patient with acute necrotizing pancreatitis. Can a simple microscope specimen save a patient's life? A case report. J Clin Case Rep 2015;5:662.
70. Stoicescu M. Acute pancreatitis after therapy with GABARAN. J Develop Drugs 2015;5:146.
71. Zhang LC, et al. Hyper-homocysteinemia; A potential indicator of acute pancreatitis. J Bioengineer & Biomedical Sci. 2016;S3:002.
72. Lukacs K, et al. Primary hyperlipidemia, acute pancreatitis and ketoacidosis in an adolescent with type 2 diabetes. J Diabetes Metab. 2016;7:651.
73. Sato Y, et al. Anesthetic management of a patient who underwent emergent cesarean section after sudden disturbance of consciousness caused by disseminated intravascular coagulation due to severe urine infection and septic shock. J Anesth Clin Res. 2016;7:613.
74. Vallianou NG, et al. Elevated D-dimers without disseminated intravascular coagulation in a patient with adult onset still's disease; An indicator for early corticosteroid treatment? Rheumatology (Sunnyvale). 2015;5:151.
75. Igari K, et al. A case of disseminated intravascular coagulation caused by a ruptured abdominal aortic aneurysm for which recombinant human soluble thrombomodulin was effective. J Vasc Med Surg. 2013;1:109.
76. Singh K, et al. Renal hilum study for anomalous vasculature. Anat Physiol. 2016;6:230.
77. Matsumura G and Shinoka T. First report of histological evaluation of human tissue-engineered vasculature. J Biotechnol Biomater. 2015;5:200.
78. Nishijima Y and Beyer AM. H2S in the Vasculature; Controversy of mechanisms in physiology, pathology and beyond. Cardiol Pharmacol. 2015;4:135.
79. Raja SMN, et al. Analysis of vasculature detection in human retinal images using bacterial foraging optimization based multi thresholding. Int J Swarm Intel Evol Comput. 2014;4:107.
80. Larimer BM and Deutscher SL. Identification of a peptide from in vivo bacteriophage display with homology to egfl6; A candidate tumor vasculature ligand in breast cancer. J Mol Biomark Diagn. 2014;5:178.
81. Suna W and Zhonga Z. Epithelial Wnt ligands regulate pulmonary vasculature development. J Pulm Respir Med. 2014;4:176.
82. Kolka CM. Treating diabetes with exercise-focus on the microvasculature. J Diabetes Metab. 2013;4:308
83. Munira S, et al. Evaluation of therapeutic efficiency of hilsha fish oil on cardiovascular disease and hepatic disease marker in hypercholesterolemic mice. Biol Med (Aligarh). 2015;7:254.
84. Lerolle N, et al. High frequency of advanced hepatic disease among hiv/hcv co-infected patients in cambodia; The HEPACAM sudy (ANRS 12267). J AIDS Clinic Res. 2012;3:161.
85. Hiroshi M, et al. Clinicopathological Significance of fatty acid synthase expression in extrahepatic cholangiocarcinoma. Oncol Cancer Case Rep. 2016;2:117.
86. Elbasateeny SS, et al. Diagnostic discrimination of fine needle aspiration specimens of hepatic nodules using immunohistochemical expression of GPC3 and EZH2. J Tumor Res. 2016;2:110.
87. Raphael KC, et al. Hepatic encephalopathy; Prevalence, precipitating factors and challenges of management in a resource-limited setting. J Gastrointest Dig Syst. 2016;6:441.

88. Yang J, et al. The effects of acetylation of pten on hepatic gluconeogenesis. J Alzheimers Dis Parkinsonism. 2016;6:243.
89. Nikhil A, et al. High Protein/fish oil diet prevents hepatic steatosis in NONcNZO10 mice; Association with diet/genetics-regulated micro-RNAs. J Diabetes Metab. 2016;7:676.
90. Sagor MAT, et al. Fresh seed supplementation of syzygium cumini attenuated oxidative stress, inflammation, fibrosis, iron overload, hepatic dysfunction and renal injury in acetaminophen induced rats. J Drug Metab Toxicol. 2016;7:208.
91. Chen Y, et al. Hepatic epithelioid hemangioendothelioma with cecal metastasis in a natural course;a case report. J Cytol Histol. 2016;7:398.
92. Mohapatra S, et al. Implantable magnetic-dielectric composites for prolonged hyperthermia treatment of hepatic lesions. J Biotechnol Biomater. 2016;6:230.
93. Bouwman FG, et al. In vitro, in vivo comparison of cyclosporin a induced hepatic protein expression profiles. J Clin Toxicol. 2016;6:299.
94. Ehsan NA, et al. Utility of immunohistochemistry in the diagnosis of a case of hepatic angiomyolipoma from a tertiary referral centre for liver diseases. J Hepatol Gastroint Dis. 2016;2:131.
95. Bhatia S, et al. Safety and efficacy of new oral anticoagulants in patients with atrial fibrillation; A literature review. J Diabetic Complications Med. 2015;1:101.
96. Carnes EB, et al. Role of novel oral anticoagulants in primary and secondary thromboprophylaxis in cancer. J Hematol Thrombo Dis. 2015;3:222.
97. Ragab G and Mattar M. Oral direct anticoagulants in thrombosis management in anti-phospholipid syndrome; Unanswered questions. J Hematol Thrombo Dis. 2015;3:208.
98. Turiel M, et al. Practical guide to the new oral anticoagulants. J Gen Pract. 2015;3:194.
99. Micco PD, et al. Baseline analysis on the outcome of patients with deep vein thrombosis (DVT) before the global impact of new oral anticoagulants in italy; Data from riete registry. J Blood Lymph. 2014;4:129.
100. Cox JL. Practical management of stroke prevention in patients with atrial fibrillation and renal impairment receiving newer oral anticoagulants; Focus on rivaroxaban. J Gen Pract. 2014;2:144.
101. Patel S, et al. Effectiveness of pharmacy run anticoagulation clinics compared to large clinical trials of new oral anticoagulants. J Pharma Care Health Sys. 2014;1:101.
102. Sairaku A, et al. How to use novel oral anticoagulants during the periprocedural period of atrial fibrillation ablation. Pharm Anal Acta. 2014;5:294.